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The human respiratory tract is exposed to environmental irritants on a daily basis. 
The innate immune system is composed of different cellular components 
including the resident airway epithelium and macrophages and acts as the first 
line of defense to protect the lung against inhaled irritants. Activation of innate 
immune pathways is associated with the release of different mediators like 
cytokines, chemokines, lipid mediators and complement factors to mediate the 
recruitment of different immune cells into the airway lumen. The role of the innate 
immune system in chronic airways disease is currently a major area of research 
in the field and the focus of this thesis. 
 
RAGE and TLR4 are two major innate immune receptors implicated in the 
pathogenesis of asthma and COPD. We used TLR4, RAGE and TLR4/RAGE 
deficient mice to study the individual and combined role of these receptors in the 
airway response to acute cigarette-smoke exposure. We found that RAGE but 
not TLR4 deficiency protected against cigarette-smoke induced neutrophilic 
airway inflammation, mediator release and airway hyperreactivity (AHR). 
Interestingly, TLR4 deficiency exacerbated AHR. Together these findings, 
suggest that RAGE rather than TLR4 should be pursued as a therapeutic target 
in COPD. 
 
In contrast to our findings above however, we found that dual inhibition of 
TLR4/RAGE signaling, but not individual inhibition of these receptor pathways, 
protects against corticosteroid-resistant airway neutrophilia and AHR in an 
experimental model of severe asthma. Also, by performing a global 
xviii 
  
phosphoproteomics analysis of lung tissue samples, we identified novel signaling 
pathways activated down-stream of TLR4/RAGE ligation in severe experimental 
asthma.  
 
We also investigated the role of macrophage migration inhibitory factor (MIF) in 
severe asthma. We demonstrated increased expression of MIF, S100A8/A9 and 
TLR4, and reduced expression of annexin A1 (ANXA1) in subjects with 
predominant airway neutrophilic inflammation. We also demonstrated that MIF 
inhibition protects against corticosteroid-resistant neutrophilic inflammation and 
airway hyperreactivity, and restores corticosteroid sensitivity in an experiental 
mouse model of severe asthma. Beneficial effects of MIF inhibition were 
associated with inhibition of S100A8 and CCL11 protein in the bronchoalveolar 
lavage fluid and reduced proteolytic cleavage of ANXA1. While ISO-1 had no 
effect on the secretion of pro-neutrophilic mediators, including IL-1 family 
cytokines, it did render these pathways sensitive to inhibition by dexamethasone. 
 
Finally, we identified a role for FhHDM-1, an immunomodulatory peptide derived 
from liver fluke Fasciola hepatica as a novel therapeutic treatment for asthma. 
Administration of FhHDM-1 protected against eosinophilic and neutrophilic 
inflammation, mucus secretion and AHR in a mouse model of house-dust mite 
induced asthma.  
 
In summary, the studies in this thesis have uncovered new molecular 
mechanisms of innate immune activation associated with the inception and 
xix 
  
progression of COPD and severe asthma, and have identified a novel helminth-
based therapy for the treatment of asthma.   
 
